Personal Genome Sequencing Identifies Mutation Linked to Charcot-Marie-Tooth Disease

CARLSBAD, Calif., Mar 10, 2010 (BUSINESS WIRE) -- Scientists using advanced genomic analysis technologies from Life Technologies Corporation (NASDAQ: LIFE) have sequenced an individual's genome and identified the specific causative mutation associated with Charcot-Marie-Tooth Disease (CMT), one of the most common inherited neurological disorders currently affecting 1 in 2,500 individuals in the United States.

In a paper published today by The New England Journal of Medicine (NEJM),Baylor College of Medicine doctors Richard Gibbs and James R. Lupski used whole genome sequencing for the first time to identify the cause of an inherited disease. Lupski, a doctor and geneticist affected by the motor and sensory nerve function disorder since his early childhood, identified the genetic variant within his genome. Lupski, who comes from a family of 10 where he and three of his eight siblings have been affected by CMT, has been searching for the genetic mutation causing his disease for more than 20 years. The groundbreaking discovery of this mutation demonstrates the power of DNA sequencing to pinpoint the cause of genetic disease and ultimately lead to the development of new therapies.

Gibbs and Lupski worked together at Baylor's Human Genome Sequencing Center (HGSC), and used the Applied Biosystems SOLiD(TM) System, an ultra high throughput next-generation genomic analysis platform, to find the mutation implicated in CMT.

CMT primarily affects the human body's peripheral nerves, which exist outside the brain and spinal cord and supply the muscles and sensory organs in the limbs. Individuals with CMT may have weak lower leg and foot muscles, which may affect stride or result in foot deformities. It is not uncommon for muscle weakness to also occur in the hands, resulting in difficulty with fine motor skills. The severity of CMT varies in different individuals and even among family members with the disease.

Gibbs and Lupski used the SOLiD System to generate comprehensive sequence data of Lupski's entire personal genome, enabling the scientists to identify the key DNA mutations connected to Lupski's type of CMT. The platform's ability to achieve the life science industry's highest accuracy at a minimum depth of genome coverage demonstrates proof-of-principle for whole genome sequencing as a medical diagnostic for human disease. Based on the success of this research collaboration between Life Technologies and the HGSC, scientists at Baylor will now begin to apply this methodology to the discovery of rare genetic variants in the other 12,000+ genetic diseases.

"I've dedicated most of my career to understanding the genetic basis of CMT for very personal reasons," said Dr. Lupski, Cullen Professor and Vice Chair for the Department of Molecular and Human Genetics at Baylor College of Medicine. "By having a better understanding of this disease, my hope is that we - the healthcare industry and individuals affected by CMT - will be able to better mitigate its consequences."

"Translational research studies uncovering novel genetic information are maximized through collaborative efforts between industry and the research community," said Dr. Gibbs, Director of Human Genome Sequencing at Baylor College of Medicine. "I believe the CMT research enabled through our relationship with Life Technologies represents the best demonstration of disease-related data to date."

"The elucidation of this genetic mutation using high-throughput sequencing is a powerful statement about the use of advanced genome analysis technologies as a discovery and diagnostic research tool and will help accelerate the promise of personalized medicine," said Shaf Yousaf, President of Genomic Analysis for Life Technologies. "There is tremendous opportunity to apply this research as proof-of-principle and rapidly advance the discovery of other rare genetic variants associated with disease."

PBS' To the Contrary, hosted by Bonnie Erbé, has developed a three-part series called "Decoding DNA: Helping Children With Rare Diseases." The program looks at genetic mapping and finding cures for children with rare diseases like Charcot-Marie-Tooth Disease. To view the first two parts of the series, please visit PBS at the links below. Part 3 will be shown later this month. Please view your local listing for further information.

Part 1: http://www.pbs.org/ttc/bth_video/dna_pt1.html
Part 2: http://www.pbs.org/ttc/bth_video/dna_pt2.html

About Life Technologies (http://www.lifetech.com/)

Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of $3.3 billion in 2009, employs approximately 9,000 people, has a presence in 160 countries, and possesses a rapidly growing intellectual property estate of approximately 3,900 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc., and manufactures both in-vitro diagnostic products and research use only-labeled products. For more information on how we are making a difference, please visit us online at http://www.lifetechnologies.com/. Follow Life Technologies on Twitter @LIFECorporation and on Facebook.

Safe Harbor Statement

This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

For Research Use Only. Not for use in diagnostic procedures.

SOURCE: Life Technologies Corporation

Life Technologies
Patty Zamora, 760.476.7818
patty.zamora@lifetech.com